This inventor holds 3 USPTO granted patents. Top assignees: Rhone-Poulenc Rorer S.a., Other. Active years: 2001-2004.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 247 
2 out of 834,513 Years Active: 2001-2004
Title: Hedi Mohamed Haddada: Innovator in Adenoviral Therapeutics
Introduction
Hedi Mohamed Haddada is a notable inventor based in Alfortville, France. She has made significant contributions to the field of biotechnology, particularly in the development of adenoviral vectors for therapeutic applications. With a total of 3 patents, her work focuses on innovative solutions for antitumor treatments.
Latest Patents
Haddada's latest patents include groundbreaking inventions that utilize recombinant adenoviruses. One of her notable patents is titled "Defective recombinant adenoviruses expressing cytokines for antitumor treatment." This invention involves a recombinant nucleic acid designed to produce a defective adenovirus that contains an inserted sequence coding for a cytokine. This cytokine is regulated by a promoter within the genomic sequence of the recombinant adenovirus. The resulting adenovirus is instrumental in creating anti-tumoral drugs that can be directly injected into the tumor of the host. Another significant patent is "Adenoviral vectors of canine origin," which describes the use of a recombinant adenovirus of animal origin containing a heterologous DNA sequence. This invention is aimed at preparing a pharmaceutical composition for therapeutic and surgical treatments in humans.
Career Highlights
Throughout her career, Hedi Mohamed Haddada has worked with prominent companies in the biotechnology sector, including Rhone-Poulenc Rorer S.A. Her expertise in adenoviral technology has positioned her as a key figure in the development of innovative therapeutic solutions.
Collaborations
Haddada has collaborated with esteemed colleagues in her field, including Michel Perricaudet and Manuel Lopez. These partnerships have contributed to her success and the advancement of her research.
Conclusion
Hedi Mohamed Haddada's contributions to biotechnology, particularly in the area of adenoviral therapeutics, highlight her innovative spirit and dedication to improving cancer treatment options. Her patents reflect a commitment to advancing medical science and providing new solutions for patients.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile